ONO 4915
Alternative Names: ONO-4915Latest Information Update: 28 Nov 2025
At a glance
- Originator Ono Pharmaceutical
- Class Bispecific antibodies
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders